Brahms' procalcitonin test:
This article was originally published in Clinica
Executive Summary
Brahms has received US 510(k) clearance of its procalcitonin (PCT) Kryptor test to assess patients' risk for severe sepsis and septic shock. The test, which provides results in less than an hour, will be used in critically ill patients in the intensive care unit to determine whether an infection is bacterial or viral. Bacterial infections can be treated quickly with antibiotics, while these drugs can be avoided in patients with viral infection (inappropriate use of antibiotics contributes to the increase in antibiotic-resistant bacteria). PCT levels are undetectable in healthy people, but bacterial infections cause levels to rise. This is not seen with viral infections. The first automated PCT test to reach the US market, bioMerieux's VIDAS B.R.A.H.M.S PCT test (licensed from Hennigsdorf, Germany-based Brahms in 2005), was approved in the US last October.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.